Vera Therapeutics, Inc. maintains a Hold rating as atacicept progresses toward potential FDA approval for IgA nephropathy, with a BLA filing on track this quarter. Atacicept's Phase 3 ORIGIN trial met ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today announce the U.S. Food and Drug Administration ...

What Is Voyxact, and Why Does It Matter? Voyxact (sibeprenlimab-szsi) is a new medicine approved by the FDA to lower protein levels in urine for adults with a kidney condition called primary ...

Sibeprenlimab is approved for IgAN treatment, showing a 51.2% reduction in proteinuria in the VISIONARY trial. Administered subcutaneously every four weeks, it inhibits APRIL to reduce IgA levels.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Povetacicept substantially reduced proteinuria with stable eGFR over 48 weeks in patients with IgAN or pMN, according to interim data from the phase 1/2 RUBY-3 trial. Povetacicept safely reduces ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) presented new interim data for its investigational therapy povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) at the ...

Please provide your email address to receive an email when new articles are posted on . IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and a leading cause of chronic ...

Tesla is making headlines again with the return of its Mad Max mode in Full Self-Driving (Supervised). This feature, designed to make the car drive more aggressively, has arrived just as the automaker ...

Earlier this month, Tesla rolled out a new firmware update that added a pair of new driving modes for the controversial full self-driving (FSD) feature. One, called “Sloth,” relaxes acceleration and ...

As the industry's competition in the rare kidney disease IgA nephropathy (IgAN) heats up in the U.S., Roche’s Chugai Pharmaceutical is making an M&A play to advance a leading contender across the ...

This won't be a long one. The Phillies are almost certainly not going to be bringing back Max Kepler next season, after the free agent played one mediocre year in Philadelphia. "Max Kepler I think did ...